×
More Charts Below
Shandong Weigao Medical Polymer Price to Free Cash Flow Ratio 2012-2024 | SHWGF
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Recent Trends
Shandong Weigao Medical Polymer price to free cash flow ratio from 2012 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$227.2B
Boston Scientific (BSX)
$140.7B
Stryker (SYK)
$132.3B
EssilorLuxottica (ESLOY)
$128.4B
Medtronic (MDT)
$105.9B
Lonza Group Ag (LZAGY)
$47.4B
Haleon (HLN)
$46.2B
ResMed (RMD)
$31.3B
Agilent Technologies (A)
$29.2B
GE HealthCare Technologies (GEHC)
$28.6B
Terumo (TRUMY)
$28.2B
Koninklijke Philips (PHG)
$22.2B
Zimmer Biomet Holdings (ZBH)
$19.4B
Insulet (PODD)
$17.3B
Baxter (BAX)
$14.8B
Smith & Nephew SNATS (SNN)
$11.4B
Sunny Optical Technology (SNPTF)
$7.6B
Lantheus Holdings (LNTH)
$6.9B
Bio-Rad Laboratories (BIO)
$6.7B
Demant (WILYY)
$6.6B
Prestige Consumer Healthcare (PBH)
$4B
Perrigo (PRGO)
$3.5B
ICU Medical (ICUI)
$3.4B
Haemonetics (HAE)
$2.9B
Envista Holdings (NVST)
$2.6B
GN Store Nord (GNNDY)
$2.2B
LeMaitre Vascular (LMAT)
$1.9B
QuidelOrtho (QDEL)
$1.7B
AtriCure (ATRC)
$1.6B
Kestra Medical Technologies (KMTS)
$1.2B